ArticleDiabetology & metabolic syndrome2021
The best drug supplement for obesity treatment: a systematic review and network meta-analysis.
Article in Diabetology & metabolic syndrome, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.International journal of obesity (2005) · 2023 · on this mapPooled it
- Trial
- Article
- Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity.Cureus · 2023Article
- Correcting calculation and data errors reveals that the original conclusions were incorrect in "The best drug supplement for obesity treatment: a systematic review and network meta-analysis".Diabetology & metabolic syndrome · 2023Article
- Obesity and the risk of cardiometabolic diseases.Nature reviews. Cardiology · 2023Review
- Pharmacological Support for the Treatment of Obesity-Present and Future.Healthcare (Basel, Switzerland) · 2023Review
- Pharmacological Treatments and Natural Biocompounds in Weight Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Best Surgical Treatment for Cervical Radiculopathy: A Systematic Review and Network Meta-Analysis.Advanced biomedical research · 2023Review
- Review
- Correction to: The best drug supplement for obesity treatment: a systematic review and network meta-analysis.Diabetology & metabolic syndrome · 2022Article
- L-Serine Supplementation Blunts Fasting-Induced Weight Regain by Increasing Brown Fat Thermogenesis.Nutrients · 2022Article
Corrections and comments
- Retraction · 2023-04-17Objections by Author(s) · Unreliable Data · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) ·
- Correction · 2022-05-07Error in Data · Error in Text · Updated to Retraction · Upgrade/Update of Prior Notice(s) ·
- Expression of concern · 2021-12-23Concerns/Issues about Data · Unreliable Data · Updated to Correction ·
- Erratum issued
- Retracted
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundObesity is a complex disease with an increasing prevalence worldwide. There are different weight-management options for obesity treatment, including dietary control, exercise, surgery, and medication. Medications are always associated with different responses from different people. More safety and efficacy of drugs with fewer side effects are valuable for any clinical condition. In this systematic review and network meta-analysis, different anti-obesity drugs are compared to identify the most effective drug.
methodsAll relevant studies were extracted by searching national and international databases of SID, MagIran, ProQuest, PubMed, Science Direct, Scopus, Web of Science (WoS), and Google Scholar without time limit until October 2020. Finally, the meta-analysis was performed with the 11 remaining studies containing 14 different drug supplements. The standardized mean difference (SMD) was calculated at a 95% confidence interval (CI) to evaluate the effects of each treatment group compared with placebo. A random-effect model was used to evaluate the effect of individual studies on the final result. Heterogeneity and incompatibility of the network were assessed by Cochran's Q and Higgins I
resultsOur results showed that there were significant mean effects in people intervened with Phentermine 15.0 mg + Topiramate 92.0 mg, Phentermine 7.5 mg + Topiramate 46.0 mg, Pramlintide, Naltrexone + Bupropion 32, and Liraglutide, with SMD effects size = - 9.1, - 7.4, - 6.5, - 5.9, - 5.35, respectively.
conclusionThis study was performed to compare the effect of different drugs used for weight loss in obese patients. The most effective drugs for weight loss were phentermine and topiramate, pramlintide, naltrexone, bupropion, and liraglutide compared to placebo treatment, respectively. This study provides new insights into anti-obesity drugs and hopes to shed new light on future research to manage and treat obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.